CompletedNCT00035230
Topiramate for acute mania in bipolarity
About this title
A Study on the Safety and Efficacy of Topiramate in the Treatment of Patients With Bipolar I Disorder
Read the official source — NCT00035230This study evaluated the safety and effectiveness of Topiramate for people with bipolarity.
Medication studyAges 16+
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Topiramate for people with bipolarity.
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 16 years. Other eligibility criteria applied.
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJuly 2001
- Recruitment status
- Completed
- Enrollment listed in the registry
- 338
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Not clearly listed
- Age range
- Over 16 Years
- Official registry ID
- NCT00035230
- Official title
Show the full official title
A Randomized, Double-Blind, Multicenter, Placebo-Controlled 12-Week Study of the Safety and Efficacy of Topiramate in Patients With Acute Manic or Mixed Episodes of Bipolar I Disorder With an Optional Open-Label Extension
Get this study by email
Recruitment & locations
CompletedLocations not listed
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Topiramate for people with bipolarity.
Who is behind this study?
The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Topiramate.
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 16 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
"A Randomized, Parallel Group, Open Trial Examining the Safety, Efficacy and Tolerability of Fast Titration, 800mg/day by day 4, of Quetiapine Fumarate Compared to Standard Titration, 400mg/day by ...
Asenapine added to lithium or valproate for mania in bipolar I